

Supplementary Material

The role if Hif-1 in enhancing the radio-resistance of mouse MSCs

Irene Calvo-Asensio^{1,2}, Eugène T. Dillon³, Noel F. Lowndes^{2*}, Rhodri Ceredig^{1*}

Correspondence:

Rhodri Ceredig rhodri.ceredig@nuigalway.ie

Noel F. Lowndes noel.lowndes@nuigalway.ie

Supplementary Data and Methods

1. Generation of a Hif-1α knockout MS5 cell line using CRISPR/Cas9 technology.

1.1. CRISPR/Cas9 Strategy

The *Hif1a* gene locus, which is located on mouse chromosome 12, contains 15 exons separated by 14 introns, dispersed over 45 kb (Semenza et al., 1996; Wenger and Gassmann, 1999). In 1997, Wenger et al. described two *Hif1a* mRNA isoforms in mice, resulting from two alternative first exons (exon 1.1 and exon 1.2) and differing mainly in their 5' UTR (Figure 3.2 A) (Wenger et al., 1997). When comparing the sequence information found in the NCBI database (https://www.ncbi.nlm.nih.gov), the exon 1.2-containing transcript (Transcript Variant 1) encodes a Hif-1α protein that is 12 amino acids longer in the N-terminal region than the exon 1.1-containing isoform (Transcript Variant 3). Transcript Variant 2, also described in the NCBI database, is nearly identical to Transcript Variant 1 except for the lack of three nucleotides in the N-terminal region and a single nucleotide substitution. According to this information, three different guide RNA sequences were designed, and the wildtype endonuclease version of the Cas9 enzyme was used in order to introduce double-strand breaks at the desired sites (Cong et al., 2013). As depicted in Supplementary Figure 1, two of the gRNAs were designed in exon 1.2, in order to target *Hif1a* transcript variants 1 and 2 at both sides of the translational start codon (ATG), in an attempt to generate a deletion that would impede transcription initiation at this site. Transcript variant 3 (whose expression is driven by a tissue-specific promoter (Wenger et al., 1998)) has its translational start codon in exon 2. However, this exon is relatively short (\sim 190 bp) and no potential high quality gRNA sequences were found in it. For this reason, the third gRNA, which would target all mRNA isoforms, was designed in exon 3. Guide RNA specificity was tested by blasting the sequence against the mouse genome in order to avoid off-target effects, and its quality and predicted efficiency was assessed using two online available tools: MIT CRISPR design tool (http://crispr.mit.edu/) and the DESKGEN genome-editing tool (https://www.deskgen.com).

1.2. CRISPR/Cas9 Methodology

1.2.1. Generation of CRISPR/Cas9 plasmids

Generation of *Hif1a^{-/-}* MS5 cells was achieved using the pX330 WT Cas9 plasmid (obtained from Addgene, catalogue number #42230). Guide RNA sequences targeting the first and third exon of mouse *Hif1a* were designed manually as described above. Corresponding oligonucleotides (Supplementary Table 1) including overhangs for cloning were purchased from Sigma and reconstituted at a concentration of 100μ M in nuclease-free H₂O. 25 μ l of each oligonucleotide were incubated at 95°C for 5 min and annealed by allowing them to cool down slowly until room temperature for approximately 2 hours. The oligonucleotides were then treated with T4 polynucleotide kinase (NEB) and re-annealed as previously described.

4ug of pX330 plasmid were linearized by digestion with BbsI restriction enzyme (Thermo Scientific) and treated with Calf Intestinal Alkaline Phosphatase (CIP, from NEB). The linearized plasmid was then purified using a PCR Clean Up kit from Thermo Scientific.

1µl of a 500nM solution of the annealed oligonucleotides was used for ligation into 50ng of the linearized pX330 vector using T4 Ligase (NEB). Ligation products were then transformed into competent Top10 *E. coli*, which were grown under Ampicillin selection. Clones corresponding to each guide RNA were picked and screened by BbsI digestion. Positive clones were sequenced to confirm the presence of the oligonucleotides and the absence of mutations using the pX330 seq primer (Supplementary Table 2).

Correct clones were purified from large-scale *E. coli* cultures using the NucleoBond® Xtra Midi / Maxi-prep kit from Macherey-Nagel and re-sequenced prior to transfection.

1.2.2. CRISPR plasmids transfection into MS5 cells

106 MS5 cells were seeded in a 10 cm petri dish with 10 ml of DMEM supplemented with 10% FBS and without Penicillin/Streptomycin. 24h later, \sim 75% confluent cells were transfected using Lipofectamine reagent (Thermo Fisher Scientific) with 3µg of each gRNA/Cas9 plasmid, 1µg of pLOX Puromycin resistance plasmid for selection of transfected cells and 0.5µg of eGFP expression plasmid to test for transfection efficiency. After incubation for 24h with the transfection mixture, cells were trypsinized and serial dilutions were performed in complete medium containing 10µM of Puromycin. Spare cells not used for the serial dilutions were used to assess transfection efficiency by flow cytometry. Cells were grown under selection for 48 hours before medium with puromycin was replaced with fresh medium and cells were cultured for 14 days until colonies were clearly visible.

1.2.3. Clone selection and screening

Single colonies were picked using cloning discs (Sigma) and transferred into 12 well plates. Cultures were scaled up until three wells of a 6-well plate were obtained per clone. One well was harvested for cryopreservation, the second one for protein extraction and screening and the third one for genomic DNA extraction and characterization of the mutations introduced.

Clones were screened for the presence or absence of the Hif-1 α protein by western blotting, using treatment with 500µM of DMOG to prevent the degradation of the protein and ensure its detection. Positive clones missing the Hif-1 α band were also further characterized by PCR and sequencing to determine the exact mutations introduced in each allele.

1.3. Generation and characterization of Hif-1α-/- MS5 cells. CRISPR/Cas9 results.

Mouse MS5 cells were transfected simultaneously with a pool of the three pX330 plasmids containing the three gRNA sequences designed, in order to increase targeting efficiency. Resulting clones were screened for the presence or absence of the Hif-1 α protein by western blot. Hif-1 α protein levels are very tightly regulated and its degradation is induced within seconds in the presence of oxygen. In order to avoid Hif-1α degradation during sample preparation that would result in false positives for the protein deletion, the 95 CRISPR clones selected were treated with 500µM DMOG, a cell permeable, competitive inhibitor of prolyl hydroxylase domain-containing proteins (such as the PHDs that hydroxylate HIF-1 α in the presence of oxygen) prior to protein extraction for screening by western blot. Apart from this, genomic DNA from all these clones was also harvested in order to characterize the mutations introduced in their *Hif1a* loci. In order to characterize the targeting efficiency of the CRISPR/Cas9 strategy, 15 clones were randomly picked and gDNA regions to which the Cas9 was directed by the gRNAs were amplified by PCR and sequenced. Out of the 15 clones analyzed, 13 showed mutations in at least one exon, and only two were wild type, resulting in a targeting efficiency of ~87%. Most of these mutations had occurred at the exact sites where the Cas9 endonuclease was predicted to introduce double-strand breaks. Interestingly, when the forward primer complementary to exon 1 and the reverse primer complementary to exon 3 were used together, the gDNA from some clones gave rise to a ~400bp PCR product which was absent in the WT MS5 gDNA used as control. Sequencing of this DNA fragment revealed that it was the result of a ~20kb deletion between the Cas9 cut sites in exons 1.2 and 3 (data not shown). However, no mutations were detected at the site where the first gRNA would direct the Cas9 to cut, indicating that this particular gRNA had not worked properly. In order to investigate the reasons for this, the MS5 *Hif1a* cDNA was isolated and most of it (except for the 3'UTR and the beginning of the 5'UTR) was sequenced and compared to the reference sequence used to design the gRNAs. A total of 10 single nucleotide changes, a 1 nucleotide deletion (in the 5'UTR, so not affecting reading frame) and a 42 nucleotide deletion were detected, which result in 4 amino acid substitutions and the deletion of a fragment of 14 amino acids in the protein sequence. This 14 amino acid deletion falls in the ODD domain and had been previously described by Wenger et al. in 1996 (Wenger et al., 1996).

Unfortunately, two of the single nucleotide changes were found in the sequence of the first gRNA, explaining why it did not work.

Supplementary Figure 2 shows an example of three of the *Hif1a* knockout clones obtained: clones 41, 55 and 76. Sequencing of their gDNA (Supplementary Figure 2 B) allowed characterizing the specific mutations present in each of their two alleles (Supplementary Figure 2 C, D). Exon 3 of clone 41 presented a single-nucleotide and a two-nucleotide deletion in each allele, respectively, resulting in the disruption of the reading frame of the protein and, eventually, the introduction of a premature stop codon. Similarly, clone 55 showed two single-nucleotide insertions in exon 1 and a 40-nucleotide deletion and a 4-nucleotide insertion in each allele in exon 3. Finally, clone 76 presented a single-nucleotide deletion and a single-nucleotide insertion in exon 1 and a twonucleotide and a four-nucleotide deletions in the two alleles in exon 3. Two of these *Hif1a^{-/-}* clones (41 and 76) were selected as two independent clones for subsequent experiments.

2. Generation of Hif-1α mutant MS5 cell lines.

2.1. Design of Hif1a mutant constructs.

In December 2015, Wu et al. published a partial crystal structure of the Hif-1 transcription factor interacting with the DNA double helix (Wu et al., 2015). This crystal structure is composed of the Nterminal segments of both Hif-1 α and Arnt, thereby allowing the mapping of the main specific residues that mediate both the interaction between Hif-1 α and Arnt an also their interaction with DNA. Both Hif-1 α and Arnt are members of the helix–loop–helix-PER-ARNT-SIM (bHLH-PAS) family, and as such they are composed of an amino-terminal bHLH domain for DNA binding, PAS domains (PAS-A and PAS-B) that allow dimerization, and transactivation domains (TADs) in order to modulate their function. In addition to these, $Hif-1\alpha$ contains an Oxygen-Dependent Degradation Domain (ODDD) which is critical for its regulation and function (Supplementary Figure 3 A) (Kewley et al., 2004). In order to prevent Hif-1 α interaction with DNA, two point mutations were introduced in its bHLH domain that would result the following two amino acid substitutions: K19Q and R30Q (Supplementary Figure 3 B). These are the two positively charged amino acids that directly interact with the negatively charged DNA molecule. According to the COSMIC Database, these two specific substitutions have been found in cancer patients in which Hif-1 α function is altered (Forbes et al., 2015; Wu et al., 2015). Wu et al. 2015 also demonstrated that interaction between Hif-1α and Arnt could be abolished by mutating two single residues found in the PAS-A domain of Hif-1α: R170A and V191D (Wu et al., 2015), resulting from two double-nucleotide mutations in the Hif-1α cDNA (Supplementary Figure 3 C).

2.2. Methods for generation and transduction of lentiviral vectors

2.2.1. Hif1a cDNA cloning into pLENTI PGK Blast plasmid

Hif-1α cDNA was isolated from whole MS5 cDNA by PCR, using specific primers complementary to the start of the coding sequence in Exon 1.2 (F primer) and to the end of the coding sequence in Exon 15 (R primer) (Supplementary Table 2), finishing in the last nucleotide before the transcriptional stop codon. In addition, these primers contained overhangs corresponding to attB sites to allow cloning by Gateway cloning through a BP reaction. Amplified *Hif1a* cDNA was run on an agarose gel in order to assess specificity of the reaction. The band corresponding to the *Hif1a* cDNA predicted size (~2.5kbp) was extracted from the gel, sequenced and cloned into pDONR201 plasmid (Invitrogen) by gateway cloning.

Different clones were screened by digestion and sequencing to confirm the absence of mutations caused during the PCR amplification or the cloning process. Correct clones were purified from largescale *E. coli* cultures using the NucleoBond® Xtra Midi / Maxi-prep kit from Macherey-Nagel and re-sequenced.

bHLH- and PAS-A-mutated *Hif1a* cDNA versions were generated by site-directed mutagenesis as detailed below. Resulting plasmids were screened by sequencing and correct clones were again purified from large-scale *E. coli* cultures as previously described, and re-sequenced.

WT and mutated versions of the *Hif1a* cDNA contained in pDONR201 plasmids were cloned into the pLENTI PGK Blast plasmid (Adgene), which is a lentiviral mammalian expression vector driven by the hPGK promoter and containing a Blasticidin resistance cassette. Gateway cloning was performed through an LR reaction using the LR recombinase enzyme obtained from Invitrogen. The clones obtained were screened by enzymatic restriction and sequencing, and correct clones were purified from large-scale E. coli cultures using the NucleoBond® Xtra Maxi-prep kit (Macherey-Nagel) to achieve higher plasmid yield and concentration and sequenced.

2.2.2. Site-directed mutagenesis

In order to introduce specific mutations in the Hif-1 α cDNA, complementary pairs of primers containing the desired nucleotide changes were designed (Supplementary Table 2). The mutagenesis reaction was carried out using KOD polymerase according to the manufacturer's guidelines, using an Eppendorf Mastercycler ep Gradient S thermocycler. The products obtained were checked on a 1% Agarose gel before addition of 1.5µl of DpnI restriction enzyme directly to the mutagenesis reactions in order to eliminate the original plasmid template molecules that (unlike the newly generated mutant plasmids) are methylated and thus prone to digestion with the enzyme. Digestion reactions were incubated for $12\n-16h$ at 37° C and then transformed into competent Top10 *E. coli.* Single colonies were picked and plasmids were checked for the presence of the desired mutations by sequencing.

2.2.3. Lentiviral particle generation

 $5x10^5$ HEK293T cells were seeded per 10cm petri dish and cultured until they reached a ~70% confluency level. Each of the pLENTI PGK Blast vectors containing the different versions of the Hif-1α cDNA was mixed with the three packaging plasmids psPAX2, pMS2.g and Rev plasmids as indicated in Table 3.6, and diluted in a 150mM NaCl solution up to a 250µl volume. 40µl JET-PEI transfection reagent (Polyplus) were mixed with 210µl of a 150mM NaCl solution and incubated at room temperature for 5min prior to mixing it with the plasmid mix previously prepared and incubating this new mixture for 20min at room temperature.

HEK293T cell growth medium was replaced with 10ml fresh DMEM containing 10% heatinactivated FBS and 1% penicillin-streptomycin solution. After incubation, pDNA/JET-PEI mix was added gently to the tissue culture plates, and mixed well. Cells were then cultured for 24-48 hours at 37° C and 5% CO₂ in humidified incubators in order for the virus particles to be produced.

24h and 48h after transfection, cell culture supernatant (now containing viral particles) was harvested, and replaced with fresh medium. Supernatants were filtered through a 45nm filter and stored at 4° C for up to a week or at -80 $^{\circ}$ C long term.

2.2.4. Viral transduction of MS5 cells

Hif1a^{-/-} MS5 cells were seeded in 6-well tissue culture plates at low density (10^5 cells per well) to be \sim 30% confluent the next day. After 24h, tissue culture medium was removed and substituted with 2ml of undiluted viral supernatant. Plates were then spun down at 400g for 90min, at room temperature, to increase viral transduction efficiency, and then transferred to the cell culture incubator. 24h after, viral supernatant was removed and fresh medium was added. Cells were then allowed to recover for 24h before adding blasticidin at a concentration of 50µg/ml (this optimal concentration had been previously determined by performing a kill curve with the *Hif1a^{-/-}* MS5 cells) for selection of cells that had successfully integrated the transgenes. Cells were kept under selection for one week prior to performing any experiments with them.

2.3. Generation and characterization of Hif-1α mutant MS5 cell lines.

Once the desirable mutations had been introduced, three different versions of the *Hif1a* cDNA (WT cDNA, bHLH-mutated cDNA and PAS-A-mutated cDNA) were cloned into. Lentiviral particles were generated as described above and Hif- $1\alpha^{-1}$ MS5 cells were transduced with the different cDNA expression constructs and also an empty vector to be used as control for the subsequent experiments. After selection, expression of the Hif-1 α proteins was assessed by western blot. As shown in Supplementary Figure 4 A, lentiviral transduction with the three Hif-1 α constructs resulted in an over-expression of the Hif-1α proteins when compared with WT MS5 cells, in hypoxia. Interestingly, the recombinant proteins were regulated in the same fashion as the endogenous Hif-1 α , showing high protein levels in hypoxia (2% O₂) but very low levels in normoxia (21% O₂). The WT cDNA and PAS-A-mutated cDNA transduced cell lines showed the highest Hif-1α expression, while the levels of the bHLH-mutated Hif-1α protein were slightly lower, maybe due to an effect of the mutations on protein stability, although this was not confirmed.

Immunofluorescence staining was used to assess subcellular localization of the Hif-1α recombinant proteins in order to confirm their correct translocation to the nucleus, where Hif-1α performs its functions. In line with the previous western blot results, in hypoxia, the recombinant Hif-1 α proteins were over-expressed when comparison with the WT MS5 cells, while their levels were extremely low in normoxia (Supplementary Figure 4 B). In addition, proper translocation to the nucleus in hypoxia was confirmed by co-localization of the Hif-1 α signal with the DAPI used to stain the nuclei. Hif-1 α staining revealed a homogeneous pan-nuclear staining and exclusion from the nucleolus, in line with the previous literature in the field (Taylor et al., 2016).

3. Immunofluorescence microscopy methods

Cells were cultured on glass coverslips in 21% or 5% O₂ for 48 hours prior to irradiation. All cultures were fixed in 4% paraformaldehyde (Sigma Aldrich) and permeabilized in 0.1% Triton®-X100 solution. Unspecific antibody binding was prevented by blocking with 5% FCS / 2% Goat Serum / PBS for 1h at 37°C. Cells were then stained with anti-Hif-1 α primary antibody (Abcam) (1:50 dilution in blocking buffer) for 1h at 37° C and washed 3x with PBS before staining with FITCconjugated goat anti-rabbit secondary antibody $(1:200$ dilution in blocking buffer) for 1h at 37° C. Cultures were washed 3x with PBS and nuclei were counterstained with DAPI-containing Vectashield antifade mounting medium (Vector Labs). All images were captured using 40X magnification on a Delta Vision integrated microscope system (Applied Precision) controlled by SoftWoRx software mounted on an IX71 Olympus microscope. Images were processed and analysed using Fiji (Schindelin et al., 2012).

4. Label-free proteomic extended methods

Protein isolation:

Protein was isolated with the addition of trichloroacetic acid (20%). After centrifugation at 14,000rpm for 10mins and aspiration, cell pellets were twice washed in ice-cold acetone with centrifugation repeated. Protein pellets were resuspended in buffer of 8M Urea in 50mM Ammonium Bicarbonate (NH₄HCO₃). Protein concentration was determined using the Bradford Assay.

In-solution digestion:

Cysteine of plasma protein samples were reduced using dithiothreitol followed by alkylation with iodoacetamide. Dithiothreitol, iodoacetamide and urea concentrations were diluted using 50mM $NH₄HCO₃$ before Trypsin SinglesTM proteomic grade (Sigma) was added, ensuring a urea concentration lower than 2M. Digestion was carried out overnight at 37°C. After drying in vacuum centrifuge, peptides were acidified by trifluoroacetic acid (TFA), desalted with c18 STAGE tips (Rappsilber et al., 2007), and resuspended in 0.1% TFA.

Mass Spectrometry:

Peptide fractions were analyzed on a quadrupole Orbitrap (Q-Exactive, Thermo Scientific) mass spectrometer equipped with a reversed-phase NanoLC UltiMate 3000 HPLC system (Dionex LC Packings, now Thermo Scientific). Peptide samples were loaded onto C18 reversed phase columns (5 cm length, 75 µm inner diameter) and eluted with a linear gradient from 8 to 40% acetonitrile containing 0.5% TFA in 60 min at a flow rate of 3 μ L/min. The injection volume was 5 μ l. The mass spectrometer was operated in data dependent mode, automatically switching between MS and MS2 acquisition. Survey full scan MS spectra $(m/z 350 - 1600)$ were acquired in the Orbitrap with a resolution of 70,000. MS2 spectra had a resolution of 17,500. The twelve most intense ions were sequentially isolated and fragmented by higher-energy C-trap dissociation.

Protein identification:

Raw data from the Orbitrap Q-Exactive was processed using MaxQuant version 1.5.1.0 (Cox and Mann, 2008; Tyanova et al., 2016a), incorporating the Andromeda search engine (Cox et al., 2011). To identify peptides and proteins, MS/MS spectra were matched to the Uniprot *mus musculus* database (2016–10) containing 50,306 entries. All searches were performed with tryptic specificity allowing two missed cleavages. The database searches were performed with carbamidomethyl (C) as fixed modification and acetylation (protein N terminus) and oxidation (M) as variable modifications. Mass spectra were searched using the default setting of MaxQuant namely a false discovery rate of 1% on the peptide and protein level. For the generation of label free quantitative (LFQ) ion intensities for protein profiles, signals of corresponding peptides in different nano-HPLC MS/MS runs were matched by MaxQuant applying a mass accuracy of at least 20 ppm and a maximum time window of 1 min (Cox et al., 2014).

Proteomic data analysis:

The Perseus statistical software (version 1.4.1.3) was used to analysis the LFQ intensities. Protein identifications were filtered to eliminate the identifications from the reverse database and common contaminants and the total number of proteins remaining was defined as the number of proteins identified. Data was log transformed and t-test comparison of fractions carried out. For tests derived from volcano plots, missing values were imputed with values from a normal distribution and a t-test comparison was performed. For visualization using heat maps, the dataset was normalized by z-score (Deeb et al., 2012; Tyanova et al., 2016b). The Metascape online tool (http://metascape.org) was used for GO term enrichment analysis (Tripathi et al., 2015).

5. Antibodies

For western blotting, anti-Hif-1α (EPR16897) rabbit monoclonal antibody (Abcam), anti-Hif-1b (Arnt) (2B10) mouse monoclonal antibody (Novus Biologicals), anti-phospho-Histone H2A.X (Ser139) mouse monoclonal antibody (Millipore), anti-H2AX rabbit polyclonal antibody (Abcam), anti-β-Actin rabbit polyclonal antibody (Sigma-Aldrich), Pierce horseradish peroxidase (HRP) conjugated rabbit anti-mouse IgG antibody, Immuno-Pure HRP-conjugated goat anti-rabbit IgG antibody (Thermo Scientific), IRDye® Goat anti-Mouse and Goat anti-Rabbit IgG (LiCor) were used. For immunofluorescence staining, anti-Hif-1α (EPR16897) rabbit monoclonal antibody (Abcam) and fluorescein (FITC)-conjugated AffiniPure F(ab0)2 fragment goat anti-mouse IgG antibody were used.

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure 1: *Hif1a knockout CRISPR/Cas9 strategy*. **(A)** Mouse *Hif1a* genomic locus and cDNA structure. Untraslated regions are shown in white while translated regions are shown in gray. Two alternative ATG sites are indicated with green arrowheads, while stop codon (TGA) is indicated in red. **(B)** Hif-1α CRISPR/Cas9 knockoout strategy. Guide RNAs designed according to the two alternative first exons described in Wenger et al. 1998. Cas9 cut sites are indicated by red arrows. ATG in first exon is indicated in bold.

Supplementary Figure 2: *Generation of Hif1a knockout MS5 cell line using CRISPR/Cas9 technology*. **(A)** Representative western blot showing three of the Hif-1 α^{-1} MS5 cell lines obtained (Clones 41, 55 and 76). **(B)** Sequencing raw data corresponding to WT and mutated Hif1a exon 3. Specific mutations present in each allele of **(C)** exon 1 and **(D)** exon 3 of the *Hif1a* genomic locus of *Hif1a*^{-/-} MS5 clones 41, 55 and 76. Cas9 cut sites are indicated with red arrows.

Supplementary Figure 3: *Design strategy of MS5 cell lines containing WT and mutant Hif-1α cDNA.* Schematic representation of **(A)** Hif-1*α wild type* (WT) and mutant proteins with **(B)** defective interaction with DNA (Hif- $1\alpha^{K19Q/R30Q}$) (bHLH-mutated) or (C) defective interaction with Arnt (Hif- $1\alpha^{R170A/V191D}$) (PAS-A-mutated). Mutated nucleotides and amino acids are shown in red, while the original codons and amino acids are indicated in blue.

Supplementary Figure 4: *Generation of MS5 cell lines containing WT and mutant Hif1a cDNA*. Representative **(A)** Hif-1α western blot and **(B)** immunofluorescence images showing the levels of expression and subcellular localization of the Hif-1α protein in WT, *Hif1a^{-/-}*, and *Hif1a^{-/-}* MS5 transduced with the different versions of the *Hif1a* cDNA previously described (Figure 3.6) in normoxia (21% O₂) and hypoxia (2% O₂). Hif-1 α is shown in green, while DAPI is shown in blue. Scale bars represent approximately 20 μ m.

Supplementary Figure 5: *Heat maps comparing effect of hypoxia on the proteome of WT and* Hif1a^{-/-} *MS5 cells*. Heat maps with hierarchical clustering comparing the significant proteins (p <0.05) obtained trough a Log₂ transformed intensity t-test in **(A)** WT MS5 and **(B)** *Hif1a^{-/-} MS5* samples. Intensity color code represents ion current intensity (Log₂ transformed, z-score normalized).

Supplementary Figure 6: *Full X-ray film images corresponding to western blots shown in Figure 2*. Original un-cropped images of the X-ray films used to produce the western blots depicted in **(A)** Figure 2C, **(B)** Figure 2E and **(C)** Figure 2G. When necessary, films corresponding to the same western blot but different exposure times are shown.

Supplementary Figure 7: *Full LiCor scan images corresponding to western blots shown in Figure 5*. Original un-cropped LiCor scans used to produce the western blots depicted in Figure 5: **(A)** WT MS5, **(B)** $Hifla^{-1}$ MS5 clone 41, **(C)** $Hifla^{-1}$ MS5 Clone 41 transduced with and empty lentiviral vector, **(D)** WT *Hif1a* cDNA, **(E)** bHLH-mutated Hif-1α cDNA, and **(F)** PAS-A-mutated *Hif1a* cDNA lentiviral constructs.

Supplementary Figure 8: *Full X-ray film images corresponding to western blots shown in Supplementary Figure 2*. Original un-cropped images of the X-ray films used to produce the western blots depicted in Supplementary Figure 2A. Films corresponding to the same western blot but different exposure times are shown. Note that after the transfer, the membrane was cut and different pieces probed with antibodies against β-Actin and Hif-1α.

Supplementary Figure 9: *Full X-ray film images corresponding to western blots shown in Supplementary Figure 4*. Original un-cropped images of the X-ray films used to produce the western blots depicted in Supplementary Figure 4A. Note that after the transfer, the membrane was cut and different pieces probed with antibodies against β-Actin and Hif-1α.

SUPPLEMENTARY TABLES

Supplementary Table 1: *Guide RNA sequences designed for Hif1a knockout*. Overhangs for cloning are shown in blue.

Name	Sequence $(5'$ to $3')$	Exon Targeted
Guide RNA 1 Forward	CACCGGGCACCGATTCGCCATGGA	Exon 1.2
Guide RNA 1 Reverse	AAACTCCATGGCGAATCGGTGCCC	Exon 1.2
Guide RNA 2 Forward	CACCGCTCGCTCGGGCCTAAACGC	Exon 1.2
Guide RNA 2 Reverse	AAACGCGTTTAGGCCCGAGCGAGC	Exon 1.2
Guide RNA 3 Forward	CACCGCTAACAGATGACGGCGACA	Exon 3
Guide RNA 3 Reverse	AAACTGTCGCCGTCATCTGTTAGC	Exon 3

Supplementary Table 2: *Primer sequences*. Cloning overhangs are shown in blue.

Supplementary Table 3: *Results of WT MS5 proteomic analysis*. Complete list of proteins displaying significantly (p<0.05) different levels in hypoxic (2% O_2) compared to normoxic (21% O₂) WT MS5 cells.

Supplementary Material

Supplementary Table 4: *Results of* **Hif1a***-/- MS5 proteomic analysis*. Complete list of proteins displaying significantly ($p<0.05$) different levels in hypoxic (2% O₂) compared to normoxic (21% O₂) $Hifla^{-1}$ MS5 cells.

Supplementary Material

SUPPLEMENTARY REFERENCES

- Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Hsu, P. D., et al. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science (80-.).* 339, 819–823. doi:10.1126/science.1231143.Multiplex.
- Cox, J., Hein, M. Y., Luber, C. a, and Paron, I. (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol. Cell. …* 13, 2513–2526. doi:10.1074/mcp.M113.031591.
- Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–72. doi:10.1038/nbt.1511.
- Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011). Andromeda: A peptide search engine integrated into the MaxQuant environment. *J. Proteome Res.* 10, 1794–1805. doi:10.1021/pr101065j.
- Deeb, S. J., D'Souza, R. C. J., Cox, J., Schmidt-Supprian, M., and Mann, M. (2012). Super-SILAC Allows Classification of Diffuse Large B-cell Lymphoma Subtypes by Their Protein Expression Profiles. *Mol. Cell. Proteomics* 11, 77–89. doi:10.1074/mcp.M111.015362.
- Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., et al. (2015). COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res.* 43, D805–D811. doi:10.1093/nar/gku1075.
- Kewley, R. J., Whitelaw, M. L., and Chapman-Smith, A. (2004). The mammalian basic helix-loophelix/PAS family of transcriptional regulators. *Int. J. Biochem. Cell Biol.* 36, 189–204. doi:10.1016/S1357-2725(03)00211-5.
- Rappsilber, J., Mann, M., and Ishihama, Y. (2007). Protocol for micro-purification, enrichment, prefractionation and storage of peptides for proteomics using StageTips. *Nat. Protoc.* 2, 1896– 1906. doi:10.1038/nprot.2007.261.
- Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682. doi:10.1038/nmeth.2019.
- Semenza, G. L., Rue, E. A., Iyer, N. V., Pang, M. G., and Kearns, W. G. (1996). Assignment of the Hypoxia-Inducible Factor 1α Gene to a Region of Conserved Synteny on Mouse Chromosome 12 and Human Chromosome 14q. *Genomics* 34, 437–439. doi:10.1006/geno.1996.0311.
- Taylor, S. E., Bagnall, J., Mason, D., Levy, R., Fernig, D. G., and See, V. (2016). Differential subnuclear distribution of hypoxia-inducible factors (HIF)-1 and -2 alpha impacts on their stability and mobility. *Open Biol.* 6, 160195. doi:10.1098/rsob.160195.
- Tripathi, S., Pohl, M. O., Zhou, Y., Rodriguez-Frandsen, A., Wang, G., Stein, D. A., et al. (2015). Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. *Cell Host Microbe* 18, 723–35. doi:10.1016/j.chom.2015.11.002.

Tyanova, S., Temu, T., and Cox, J. (2016a). The MaxQuant computational platform for mass

spectrometry-based shotgun proteomics. *Nat. Protoc.* 11, 2301–2319. doi:10.1038/nprot.2016.136.

- Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., et al. (2016b). The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* 13, 731– 40. doi:10.1038/nmeth.3901.
- Wenger, R. H., and Gassmann, M. (1999). "Molecular Biology of Hypoxia-Inducible Factor-1," in *Molecular Biology of Hematopoiesis 6*, eds. N. G. Abraham, A. Tabilio, M. Martelli, S. Asano, and A. Donfrancesco, 269–276. doi:10.1007/978-1-4615-4797-6_34.
- Wenger, R. H., Rolfs, A., Kvietikova, I., Spielmann, P., Zimmermann, D. R., and Gassmann, M. (1997). The mouse gene for hypoxia-inducible factor-1alpha: genomic organization, expression and characterization of an alternative first exon and 5' flanking sequence. *Eur. J. Biochem.* 246, 155–165. doi:10.1111/j.1432-1033.1997.t01-1-00155.x.
- Wenger, R. H., Rolfs, A., Marti, H. H., Guenet, J. L., and Gassmann, M. (1996). Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1 alpha. *Biochem. Biophys. Res. Commun.* 223, 54–59.
- Wenger, R. H., Rolfs, A., Spielmann, P., Zimmermann, D. R., Gassmann, M., and Wenger, B. R. H. (1998). Mouse hypoxia-inducible factor-1alpha is encoded by two different mRNA isoforms: expression from a tissue-specific and a housekeeping-type promoter. *Blood* 91, 3471–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9558407.
- Wu, D., Potluri, N., Lu, J., Kim, Y., and Rastinejad, F. (2015). Structural integration in hypoxiainducible factors. *Nature* 524, 303–8. doi:10.1038/nature14883.